290 related articles for article (PubMed ID: 19181648)
1. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.
Nehra A
Mayo Clin Proc; 2009 Feb; 84(2):139-48. PubMed ID: 19181648
[TBL] [Abstract][Full Text] [Related]
2. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
Miner M; Billups KL
J Sex Med; 2008 May; 5(5):1066-1078. PubMed ID: 18331271
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
4. Sexual function in hypertensive patients receiving treatment.
Reffelmann T; Kloner RA
Vasc Health Risk Manag; 2006; 2(4):447-55. PubMed ID: 17323599
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Goldstein I; Kim E; Steers WD; Pryor JL; Wilde DW; Natanegara F; Wong DG; Ahuja S
J Sex Med; 2007 Jan; 4(1):166-175. PubMed ID: 17233782
[TBL] [Abstract][Full Text] [Related]
6. Erectile dysfunction and hypertension.
Kloner R
Int J Impot Res; 2007; 19(3):296-302. PubMed ID: 17151696
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
Blonde L
Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.
Sperling H; Gittelman M; Norenberg C; Ulbrich E; Ewald S
J Sex Med; 2011 Jan; 8(1):261-71. PubMed ID: 20807322
[TBL] [Abstract][Full Text] [Related]
9. New treatment options for erectile dysfunction in patients with diabetes mellitus.
Basu A; Ryder RE
Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
[TBL] [Abstract][Full Text] [Related]
10. Vardenafil in men with stable statin therapy and dyslipidemia.
Miner M; Gilderman L; Bailen J; Cook D; Dawson K; Stanislaus M; Beresford E; Barnes A
J Sex Med; 2008 Jun; 5(6):1455-67. PubMed ID: 18373526
[TBL] [Abstract][Full Text] [Related]
11. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Sommer F; Schulze W
World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.
Hatzimouratidis K; Burnett AL; Hatzichristou D; McCullough AR; Montorsi F; Mulhall JP
Eur Urol; 2009 Feb; 55(2):334-47. PubMed ID: 18986755
[TBL] [Abstract][Full Text] [Related]
13. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
[TBL] [Abstract][Full Text] [Related]
14. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.
Aversa A; Bruzziches R; Pili M; Spera G
Curr Pharm Des; 2006; 12(27):3467-84. PubMed ID: 17017940
[TBL] [Abstract][Full Text] [Related]
17. Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis.
Seidu S; Cebrián A; Kunutsor SK; Khunti K
Prim Care Diabetes; 2022 Oct; 16(5):601-613. PubMed ID: 36114105
[TBL] [Abstract][Full Text] [Related]
18. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.
Imprialos KP; Stavropoulos K; Doumas M; Tziomalos K; Karagiannis A; Athyros VG
Curr Vasc Pharmacol; 2018 Jan; 16(2):130-142. PubMed ID: 28595561
[TBL] [Abstract][Full Text] [Related]
19. Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes.
Palumbo PJ
Am J Med Sci; 2007 Dec; 334(6):466-80. PubMed ID: 18091369
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of PDE5 inhibitors.
Herschorn S
Can J Urol; 2003 Feb; 10 Suppl 1():23-8. PubMed ID: 12625847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
